Wednesday, November 19, 2025 The INTEGRATE trials evaluated regorafenib in advanced gastric and esophagogastric junction cancer (AGOC), a poor prognosis population. In INTEGRATE 1 (I1, phase 2), regorafenib improved progression-free survival (PFS) without a clear excess decline in health-related quality of life (HRQoL). INTEGRATE 2a (I2a, phase 3) demonstrated an overall survival (OS) benefit, alone and in a pre-specified pooled analysis with I1. Martin AJ, Soon YY, Sjoquist KM, Pavlakis N, Goldstein D, Shitara K, Simes JR. Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials (ONLINE). Gastric Cancer 2025. https://link.springer.com/article/10.1007/s10120-025-01670-2
